PREDICT乳腺癌预后模型在年轻、未接受全身治疗的淋巴结阴性乳腺癌女性中的外部验证与临床效用评估
研究基于荷兰癌症登记库1989至2000年确诊的40岁以下淋巴结阴性乳腺癌女性2264例,验证PREDICT v2.2模型的校准与区分度。模型低估10年全因死亡率33%(O/E比1.33,95%CI 1.22-1.43),整体区分度中等(10年AUC 0.65,95%CI 0.62-0.68),ER阴性者区分度差(10年AUC 0.56,95%CI 0.51-0.62)。作者认为PREDICT在该人群预测不可靠,需更新模型后方可常规使用。
要点
- PREDICT v2.2低估全部患者10年全因死亡率33%(O/E比1.33,95%CI 1.22-1.43)。
- 整体区分度中等(10年AUC 0.65,95%CI 0.62-0.68),ER阴性者区分度差(10年AUC 0.56,95%CI 0.51-0.62)。
- 仅ER阳性者中PREDICT较化疗全员策略净获益略高,ER阴性者中无此优势。
核心结论
- PREDICT对年轻淋巴结阴性乳腺癌女性的预测不可靠,需进一步更新模型后方可在该亚组常规使用。
研究设计与样本
- 研究基于荷兰癌症登记库,纳入1989至2000年确诊、年龄40岁以下、淋巴结阴性且未接受辅助全身治疗的乳腺癌女性共2264例,中位诊断年龄36岁。
- 采用观察/预期(O/E)死亡比评估校准度,采用受试者工作特征曲线下面积(AUC)评估区分度,并用决策曲线分析在预设阈值下比较PREDICT选择性化疗与化疗全员策略的临床效用。
主要发现
- 2264例中71.2%为雌激素受体(ER)阳性肿瘤,44.0%为3级肿瘤,中位肿瘤大小16 mm。
- PREDICT v2.2低估全部患者10年全因死亡率33%(O/E比1.33,95%CI 1.22-1.43)。
- 整体区分度中等(10年AUC 0.65,95%CI 0.62-0.68),ER阴性者区分度差(10年AUC 0.56,95%CI 0.51-0.62)。
- 与化疗全员策略相比,PREDICT仅在ER阳性者中显示略高的净获益,在ER阴性者中未显示净获益。
临床怎么用
- 作者认为PREDICT对年轻淋巴结阴性乳腺癌女性的预测不可靠,需进一步更新模型后方可在该亚组常规使用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The validity of the PREDICT breast cancer prognostic model is unclear for young patients without adjuvant systemic treatment. This study aimed to validate PREDICT and assess its clinical utility in young women with node-negative breast cancer who did not receive systemic treatment. METHODS: We selected all women from the Netherlands Cancer Registry who were diagnosed with node-negative breast cancer under age 40 between 1989 and 2000, a period when adjuvant systemic treatment was not standard practice for women with node-negative disease. We evaluated the calibration and discrimination of PREDICT using the observed/expected (O/E) mortality ratio, and the area under the receiver operating characteristic curve (AUC), respectively. Additionally, we compared the potential clinical utility of PREDICT for selectively administering chemotherapy to the chemotherapy-to-all strategy using decision curve analysis at predefined thresholds. RESULTS: A total of 2264 women with a median age at diagnosis of 36 years were included. Of them, 71.2% had estrogen receptor (ER)-positive tumors and 44.0% had grade 3 tumors. Median tumor size was 16 mm. PREDICT v2.2 underestimated 10-year all-cause mortality by 33% in all women (O/E ratio:1.33, 95%CI:1.22-1.43). Model discrimination was moderate overall (AUC10-year:0.65, 95%CI:0.62-0.68), and poor for women with ER-negative tumors (AUC10-year:0.56, 95%CI:0.51-0.62). Compared to the chemotherapy-to-all strategy, PREDICT only showed a slightly higher net benefit in women with ER-positive tumors, but not in women with ER-negative tumors. CONCLUSIONS: PREDICT yields unreliable predictions for young women with node-negative breast cancer. Further model updates are needed before PREDICT can be routinely used in this patient subset.
引用
- Wang Y, Broeks A, Giardiello D, et al. External validation and clinical utility assessment of PREDICT breast cancer prognostic model in young, systemic treatment-naïve women with node-negative breast cancer. Eur J Cancer. 2023. PMID: 37925965. doi:10.1016/j.ejca.2023.113401
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。